EUCTR2007-006648-23-IE进行中（未招募）1 期
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males/females age more than or equal to 12 years
- •2. Cystic Fibrosis diagnosed by either gene profiling and/or sweat test
- •3. ABPA previously diagnosed according to the Cystic Fibrosis Foundation Consensus Conference recommendations – minimal diagnostic criteria for diagnosis of ABPA in cystic fibrosis [Stevens, et al 2003]
- •4. Total serum IgE level of >500 IU/ml
- •5. Patients who are being treated for ABPA by any oral corticosteroid (OCS) (for at least 8 weeks prior to the first dose) with an OCS entry dose of minimum 5mg/maximum 40mg per day (in prednisolone equivalence) and a history of at least one unsuccessful attempt to taper steroids, defined as in the clinician’s judgment, an ABPA exacerbation during taper, OR patients with a new or recurrent acute ABPA flare, max OCS dose of 20mg.
- •6. Able to perform spirometry
- •7. Patients with an FEV1 no lower than 90% of their previous best FEV1 at screening Visit 1
- •8. FEV1 >40% (>30% is acceptable = 16 years old) of predicted (after 12 hour washout of LABA \ 6 hours of SABA)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.History of cancer in the past 10 years (except surgically-cured basal cell or squamous cell skin cancer).
- •2.Any previous history of anaphylaxis.
- •3. Any other medical condition that in the opinion of the investigator may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study.
- •4. Female patients of child bearing potential who are pregnant, breast feeding or who are either not surgically sterile, or who are sexually active and not using an acceptable form of contraception.
- •5.Prior Xolair exposure.
- •6.Lung or other transplant.
研究者
相似试验
进行中（未招募）
不适用
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosisEUCTR2007-006648-23-BEovartis Pharma Services AG60
进行中（未招募）
不适用
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergillosis - NDEUCTR2007-006648-23-ITOVARTIS FARMA60
进行中（未招募）
不适用
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosisPatients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis.MedDRA version: 9.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungMedDRA version: 9.1Level: LLTClassification code 10000244Term: ABPAEUCTR2007-006648-23-NLovartis Pharma Services AG60
已完成
4 期
An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosismucoviscidosis/cystic fibrose10010613NL-OMON33750Harrison Clinical Research Benelux30
进行中（未招募）
不适用
Safety & Efficacy of BCT197A2201 in COPD patients presenting with an exacerbatioAcute COPD exacerbationsMedDRA version: 14.1Level: LLTClassification code 10010953Term: COPD exacerbationSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-021723-27-BGovartis Pharma Services AG181